Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07453147
Recruiting Not applicable

Selective Versus Contiguous Connective Tissue Grafts in the Modified Tunnel Technique

NCT07453147 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2026-03-05

Condition(s) studied

Gum Recession

Investigational drug(s) / intervention(s)

Selective/Segmented graftContinuous graft

Selective/Segmented graft: In this group a segmented CTG will be used

Continuous graft: In this group a continuous CTG will be used

Study summary

The goal of this study is to evaluate how effective a gum grafting procedure is in treating gum recession that affects several teeth. Gum recession happens when the gum tissue pulls away from the tooth, exposing the roots. The study will look at how the treatment improves gum health, appearance, and function.

A total of 32 patients will take part in the study. All patients will be treated with a modified coronally advanced tunnel. For half of them of contiguous graft will be used, for the other half a segmented graft.

Data collected will include medical history, dental and aesthetic information, clinical measurements, and a digital scan of the mouth.

The study will include the following steps:

Before the procedure: You will have a clinical and X-ray examination to determine how much your gums have receded. A digital impression of your teeth will also be taken.

Surgical procedure: You will receive a gum graft to cover the exposed roots. This involves moving gum tissue, often taken from the roof of your mouth, to the affected areas.

After the procedure: You will have several follow-up visits over a few months to check your healing and the results of the treatment.

Study timeline:

The surgery will be done once. Follow-up visits will take place 1, 3, 6, and 12 months after the surgery. The total duration of the study is about 12 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * ASA I or ASA II * Good periodontal health * Able to undergo oral surgery * Must be 18 years old and older * No smoking * At least two teeth in the same sector in the maxilla and the right and left mandible (except in the mandibular incisive sector), of which at least 2 are contiguous, with vestibular gingival recessions of type RT 1 of 1-5mm (Cairo et al. 2011) * An identifiable or restorable cemento-enamel junction (CEJ), with or without the presence of a non-carious cervical lesion (Pini-Prato et al. 2010) * Plaque index (O'Leary 1972) and bleeding index (Ainamo et al. 1975) scores of less than 20% * Able to give informed consent and have signed the consent forms Exclusion Criteria: * Teeth showing recession associated with a carious lesion, restoration or cervical prosthesis involving CEJ * Teeth with recession depth \>5mm * Molars with recessions will be treated but will not be taken into account for the measurements * Teeth with recession that have already undergone periodontal surgery * Presence of severe tooth malposition, rotation or significant version of the tooth * Smoker and ex-smoker * Patient suffering from a disease affecting the periodontium * Patient with clinical signs of active periodontitis * Known pregnancy in progress or breastfeeding * Contraindication to surgery * Conditions or circumstances which would prevent completion of study participation or interfere with analysis of study results, such as history of no-compliance or unreliability * Patients deprived of their liberty or under legal protection

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
CHU de Liège Liège Liège Recruiting
26K Center for clinical research Paris France Not Yet Recruiting

More Centre Hospitalier Universitaire de Liege trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07453147 on ClinicalTrials.gov ↗ ← All trials in France